Abstract 450: Host-tumor immune response for breast cancer patients.

Abstract

Abstract We demonstrated immune suppression of regulatory T cells (Treg) and M2 macrophage in breast cancer (BC) patients at AACR 2011. In summary, to compare between 38 early and 12 advanced BC cases, CD163-positive tumor cells and CCR4-positive tumor cells were detected more frequently in advanced cases than in early cases. Treg cells in PBMC significantly increased in percentage of the population in 37 BC patients than in 21 healthy volunteers. To explore host-tumor immune response, several cytokines were examined in the same cases. Plasma from 32 early and 9 advanced BC cases was preoperatively obtained. Human IL-2, IL-4, IL-6, IL-10, TNF, INFγ, and IL-17A were measured using cytometric beads array system. Statistical significance was analyzed using Mann-Whitney U-test. Plasma IL-17A had significantly higher levels in early BC than in advanced BC (103 pg/ml v.s. 51 pg/ml at mean level). Th17 cells may have some potential to control tumor progression in BC. In conclusions, induction of host-tumor immune response due to chemotherapy and anti-HER2 therapy and release from immune suppression such as CCR4 monoclonal antibody are important issues to explore a new strategy for BC patients. Citation Format: Shigeru Imoto, Noriko Nakatsugawa, Hirotsugu Isaka, Hiroki Ito, Kentaro Imi, Kaisuke Miyamoto, Tetsuya Nakatsura. Host-tumor immune response for breast cancer patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 450. doi:10.1158/1538-7445.AM2013-450